Efficacy and Clinical Outcomes of Levosimendan in E-CPR

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05730907

Acronym

ECPR

Enrollment

100

Registered

2023-02-16

Start date

2023-02-20

Completion date

2023-04-30

Last updated

2023-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication

Keywords

levosimendan, ECPR, neurological outcome

Brief summary

Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation. Literature has demonstrated that ECMO initiated during advanced cardiopulmonary life support may confer superior survival rates with acceptable survival and a relatively low incidence of significant neurologic impairment. Levosimendan has not been investigated in patients with cardiac arrest who underwent Extracorporeal CPR (E-CPR). The current study aims to examine whether levosimendan use in the aforementioned patient population could improve survival and ECMO parameters.

Interventions

DRUGLevosimendan

examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Inclusion criteria

IInclusion criteria: * Hospitalized patients ≥ 18 years of age at the time of E-CPR use * Patients suffered cardiac arrest (IHCA or OHCA) * Patients received VA-ECMO for E-CPR * Criteria as per HMC's Extracorporeal Membrane Oxygenation (ECMO) for Cardiac Arrest (E-CPR) clinical practice guidelines (attached with the study protocol)

Exclusion criteria

* Patients with incomplete key data * Criteria as per HMC's Extracorporeal Membrane Oxygenation (ECMO) for Cardiac Arrest (E-CPR) clinical practice guidelines (attached with the study protocol)

Design outcomes

Primary

Measure	Time frame	Description
Survival to hospital discharge	6 months	Survival to hospital discharge with good neurological outcomes

Secondary

Measure	Time frame	Description
Survival to decannulation	6 months	Survival to decannulation with good neurological outcomes
long term survival	6 months	long term survival

Countries

Qatar

Contacts

Primary ContactRasha Kaddoura, Msc

rasha.kaddoura@gmail.com44395897

Backup ContactBssant Orabi, Msc

bassantorabi@yahoo.com44395897

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026